NervGen Pharma Corp. Common stock (NGEN) vs Sutro Biopharma, Inc. (STRO)
A side-by-side comparison of NervGen Pharma Corp. Common stock and Sutro Biopharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
NGEN
NervGen Pharma Corp. Common stock
$1.75HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
STRO
Sutro Biopharma, Inc.
$14.45HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — NGEN vs STRO
growth of $100 · dividends reinvested · last 1yNGEN -57.6% (-57.6%/yr)STRO +78.2% (+78.2%/yr)STRO compounded faster over this window
NGEN STRO
NGEN vs STRO: by the numbers
- •NGEN is the larger company ($144M vs $140M market cap).
- •Both run net losses; NGEN's is the smaller (0.00% vs -395.25% net margin).
Metrics side by side
Valuation
| Metric | NGEN | STRO |
|---|---|---|
| P/S ratio | N/A | 3.06 |
| P/B ratio | 11.81 | N/A |
Profitability
| Metric | NGEN | STRO |
|---|---|---|
| Gross margin | 0.00% | 97.20% |
| Operating margin | 0.00% | -102.41% |
| Net margin | 0.00% | -395.25% |
| ROE | -397.38% | N/A |
| ROIC | -223.90% | -100.04% |
Growth (annualized)
| Metric | NGEN | STRO |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 19.13% |
| Total return CAGR (5Y) | N/A | -39.51% |
Go deeper
Dig into the metrics
NervGen Pharma Corp. Common stock ROESutro Biopharma ROENervGen Pharma Corp. Common stock operating marginSutro Biopharma operating marginNervGen Pharma Corp. Common stock revenue growthSutro Biopharma revenue growthNervGen Pharma Corp. Common stock free cash flowSutro Biopharma free cash flow
NervGen Pharma Corp. Common stock & Sutro Biopharma appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.